MX370570B - Marcador para trastornos de la esfingomielinasa acida y sus usos. - Google Patents

Marcador para trastornos de la esfingomielinasa acida y sus usos.

Info

Publication number
MX370570B
MX370570B MX2015016844A MX2015016844A MX370570B MX 370570 B MX370570 B MX 370570B MX 2015016844 A MX2015016844 A MX 2015016844A MX 2015016844 A MX2015016844 A MX 2015016844A MX 370570 B MX370570 B MX 370570B
Authority
MX
Mexico
Prior art keywords
acid sphingomyelinase
marker
disorders
asm
sphingomyelinase disorders
Prior art date
Application number
MX2015016844A
Other languages
English (en)
Other versions
MX2015016844A (es
Inventor
Lien Chuang Wei-
f cox Gerald
X Zhang Kate
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015016844A publication Critical patent/MX2015016844A/es
Publication of MX370570B publication Critical patent/MX370570B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)

Abstract

La presente invención se refiere a métodos de evaluación, diagnóstico, control y/o tratamiento de trastornos de la esfingomielinasa ácida (ASM), tales como la enfermedad de Niemann-Pick. En particular, los métodos abarcan técnicas para diagnóstico y/o tratamiento mejorados de un trastorno de la ASM, por ejemplo usando terapia de sustitución de enzimas.
MX2015016844A 2013-06-07 2014-06-06 Marcador para trastornos de la esfingomielinasa acida y sus usos. MX370570B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
PCT/US2014/041405 WO2014197859A1 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Publications (2)

Publication Number Publication Date
MX2015016844A MX2015016844A (es) 2016-04-04
MX370570B true MX370570B (es) 2019-12-17

Family

ID=51062988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016844A MX370570B (es) 2013-06-07 2014-06-06 Marcador para trastornos de la esfingomielinasa acida y sus usos.

Country Status (29)

Country Link
US (4) US10022428B2 (es)
EP (2) EP3584580A1 (es)
JP (4) JP6457501B2 (es)
KR (3) KR102292298B1 (es)
CN (2) CN115128287A (es)
AU (5) AU2014274670B2 (es)
CA (1) CA2914751C (es)
CL (1) CL2015003563A1 (es)
CR (1) CR20150638A (es)
DK (1) DK3004896T3 (es)
EA (1) EA035342B1 (es)
ES (1) ES2762608T3 (es)
HR (1) HRP20192246T1 (es)
HU (1) HUE047863T2 (es)
IL (3) IL284102B2 (es)
LT (1) LT3004896T (es)
MA (1) MA38638B1 (es)
MX (1) MX370570B (es)
MY (1) MY185990A (es)
NZ (1) NZ754328A (es)
PH (1) PH12015502687A1 (es)
PL (1) PL3004896T3 (es)
PT (1) PT3004896T (es)
RS (1) RS59677B1 (es)
SG (2) SG10201709925SA (es)
SI (1) SI3004896T1 (es)
UA (1) UA120591C2 (es)
WO (1) WO2014197859A1 (es)
ZA (1) ZA201508630B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
PL3004896T3 (pl) * 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
SG11202001544VA (en) * 2017-08-24 2020-03-30 Sanofi Sa Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
EP4562432A2 (en) * 2022-07-28 2025-06-04 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US5773278A (en) * 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) * 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
CA2634042A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd ３次元測位システム
JP6243846B2 (ja) * 2011-11-15 2017-12-06 セントジーン アーゲー ニーマン・ピック病の診断のための方法
WO2014183873A1 (en) * 2013-05-14 2014-11-20 Centogene Ag Method for the diagnosis of niemann-pick disease
PL3004896T3 (pl) * 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania

Also Published As

Publication number Publication date
BR112015030099A2 (pt) 2017-07-25
AU2014274670B2 (en) 2017-11-09
JP6457501B2 (ja) 2019-01-23
US20240398907A1 (en) 2024-12-05
AU2023201062A1 (en) 2023-03-23
EP3584580A1 (en) 2019-12-25
WO2014197859A1 (en) 2014-12-11
CR20150638A (es) 2016-02-08
KR20210031541A (ko) 2021-03-19
PH12015502687A1 (en) 2016-03-07
HRP20192246T1 (hr) 2020-03-06
IL284102B (en) 2022-12-01
JP7414750B2 (ja) 2024-01-16
EA201592265A1 (ru) 2016-04-29
KR102292298B1 (ko) 2021-08-24
SG10201709925SA (en) 2017-12-28
AU2014274670A1 (en) 2016-01-07
US10888607B2 (en) 2021-01-12
CL2015003563A1 (es) 2016-08-05
MA38638A1 (fr) 2017-02-28
AU2018200977A1 (en) 2018-03-01
DK3004896T3 (da) 2020-01-06
KR20210104177A (ko) 2021-08-24
KR102434244B1 (ko) 2022-08-19
IL284102A (en) 2021-07-29
US11998592B2 (en) 2024-06-04
JP2016526050A (ja) 2016-09-01
US20180289778A1 (en) 2018-10-11
MA38638B1 (fr) 2018-03-30
IL298675B2 (en) 2025-12-01
PT3004896T (pt) 2019-12-23
NZ715001A (en) 2021-10-29
KR102228367B1 (ko) 2021-03-16
RS59677B1 (sr) 2020-01-31
EP3004896A1 (en) 2016-04-13
CN105474017A (zh) 2016-04-06
IL298675B1 (en) 2025-08-01
AU2023201062B2 (en) 2025-05-29
CA2914751C (en) 2023-10-03
AU2020257114B2 (en) 2023-03-16
AU2025220876A1 (en) 2025-09-11
PL3004896T3 (pl) 2020-04-30
IL284102B2 (en) 2023-04-01
AU2020257114A1 (en) 2020-11-19
US20160120958A1 (en) 2016-05-05
ZA201508630B (en) 2020-01-29
KR20160018651A (ko) 2016-02-17
HK1217534A1 (en) 2017-01-13
EP3004896B1 (en) 2019-09-18
MY185990A (en) 2021-06-14
JP2024038145A (ja) 2024-03-19
SG11201509622WA (en) 2015-12-30
ES2762608T3 (es) 2020-05-25
US20210162021A1 (en) 2021-06-03
JP2021075544A (ja) 2021-05-20
AU2018200977B2 (en) 2020-07-23
EA035342B1 (ru) 2020-05-29
MX2015016844A (es) 2016-04-04
US10022428B2 (en) 2018-07-17
JP6835806B2 (ja) 2021-02-24
UA120591C2 (uk) 2020-01-10
NZ754328A (en) 2021-12-24
HUE047863T2 (hu) 2020-05-28
IL242964B (en) 2021-07-29
IL298675A (en) 2023-01-01
CN115128287A (zh) 2022-09-30
LT3004896T (lt) 2020-01-10
JP2019089767A (ja) 2019-06-13
SI3004896T1 (sl) 2020-01-31
CA2914751A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
MX2021014047A (es) Metodos de diagnostico para tratamiento con linfocitos t.
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX2016007492A (es) Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MX2014009143A (es) Metodos y sistemas para evaluar la actividad muscular electrica en respuesta a la estimulacion de un nervio motor.
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
EP3712264A8 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
WO2013093115A3 (de) Markersequenzen für brustkrebs und deren verwendung
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
MY203831A (en) Treatment and diagnosis of inflammatory disorders
MX2016007716A (es) Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.
WO2014126796A3 (en) Methods of diagnosing, treating and monitoring diabetic retinopathy
MX352296B (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
HK1218373A1 (zh) 用於治療年齡相關失調的重組膠原蛋白7的給予
UA93327U (uk) Спосіб діагностики зрощеного перелому

Legal Events

Date Code Title Description
FG Grant or registration